These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34972781)

  • 21. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
    Bhardwaj N; Das G; Srinivasan R
    J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.
    Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
    Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
    Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
    Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
    Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis.
    Trigg RM; Turner SD; Shaw JA; Jahangiri L
    Br J Cancer; 2020 Mar; 122(7):1077-1084. PubMed ID: 32015512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
    Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
    Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
    Guimier A; Ferrand S; Pierron G; Couturier J; Janoueix-Lerosey I; Combaret V; Mosseri V; Thebaud E; Gambart M; Plantaz D; Marabelle A; Coze C; Rialland X; Fasola S; Lapouble E; Fréneaux P; Peuchmaur M; Michon J; Delattre O; Schleiermacher G
    PLoS One; 2014; 9(7):e101990. PubMed ID: 25013904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN protein stability is a better prognostic indicator in neuroblastoma.
    Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
    BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
    Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
    J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
    Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
    BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature.
    Langenberg-Ververgaert KPS; Renzi S; Chung CT; Shago M; Lo W; Davidson S; Villani A; Baruchel S; Irwin MS; Morgenstern DA
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):388-391. PubMed ID: 31094905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
    Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
    J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.